ImmunoCellular Therapeutics Announces Initiation of Phase I Trial of Cancer Vaccine ICT-121 in Recurrent Glioblastoma
LOS ANGELES--(BUSINESS WIRE)-- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced initiation of a phase I clinical trial of cancer vaccine ICT-121 as a potential treatment for patients with recurrent glioblastoma multiforme (GBM). The investigator-sponsored phase I trial is being conducted at Cedars-Sinai Medical Center in Los Angeles, CA, by Jeremy Rudnick, MD, and ImmunoCellular is supporting the trial by providing the ICT-121 vaccine. ICT-121 is a dendritic cell vaccine targeting CD133, an important cancer stem cell marker that is commonly overexpressed on a broad range of solid tumors.
The primary objective of the open label phase I trial is to assess the safety and tolerability of ICT-121. Secondary objectives include overall survival (OS) and progression-free survival (PFS) at six months after surgery as well as other response parameters. Approximately 20 patients who have had gross tumor resection and experience a first recurrence of GBM, and who are HLA-A2 positive, will be treated in the trial. Patients will be administered the vaccine once per week for four weeks during the induction phase, followed by a maintenance phase consisting of one treatment every two months until their supply of vaccine is depleted or they experience progressive disease.
"The initiation of the ICT-121 trial completes another important clinical milestone for ImmunoCellular and adds to the substantial pipeline progress we have made this year in advancing our ICT-107 phase II program in patients with newly diagnosed brain cancer," said Andrew Gengos, ImmunoCellular Chief Executive Officer. "We are positioning our company as an emerging leader in cancer immunotherapy by building our dendritic cell-based vaccine pipeline, maintaining a strong financial underpinning, and planning for the future should we achieve success in our ongoing ICT-107 phase II trial. The second half of 2013 will be an exciting time as we expect to reach the prescribed event level in the ICT-107 trial that triggers analysis of the final results."
Earlier this year, ImmunoCellular announced that the US Patent and Trademark Office (USPTO) issued a key patent application covering ICT-121. The patent includes claims covering composition of matter as well as methods of use. Specifically, the claims encompass immunogens comprising a CD133 epitope and variants thereof as well as methods of using such immunogens in immunization and to elicit cytotoxic T lymphocyte responses that are specific for tumor cells expressing the HLA-A2 antigen.
About ImmunoCellular Therapeutics, Ltd.
ImmunoCellular Therapeutics, Ltd. is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. ImmunoCellular is conducting a phase II trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor-associated antigens for glioblastoma. ImmunoCellular's pipeline also includes ICT-121, a dendritic cell vaccine targeting CD133, and ICT-140, a dendritic cell vaccine targeting ovarian cancer antigens and cancer stem cells. To learn more about ImmunoCellular, please visit www.imuc.com.
Forward-Looking Statements for ImmunoCellular Therapeutics
This press release contains certain forward-looking statements that are subject to a number of risks and uncertainties, including the risk that ICT-107, ICT-121 and ICT-140 can be further successfully developed or commercialized. Additional risks and uncertainties are described in IMUC's most recently filed quarterly report on Form 10-Q and annual report on Form 10-K. Except as permitted by law, IMUC undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
ImmunoCellular Therapeutics, Ltd.
Jane Green, 415-348-0010 (Direct) or 415-652-4819 (Mobile)
KEYWORDS: United States North America California
The article ImmunoCellular Therapeutics Announces Initiation of Phase I Trial of Cancer Vaccine ICT-121 in Recurrent Glioblastoma originally appeared on Fool.com.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.